neg or PD-L1 high bladder cancer or tumor.In addition, there is also provided a method of using an anti PD-L1 antibody therapy for bladder cancer after standard treatment or first choice therapy or relapsed after previous therapeutic regimens, after standard therapy or first choice therapy....
Programmed death 1 expression in cancer and infection: tissue versus periphery PD-1:PD-L1 blockade as host-directed therapy Anti-PD-1:PD-L1/2 therapy: improved efficacy with acceptable toxicity Anti-PD-1 versus anti-PD-L1/2 therapy and opportunities for combination with other immunotherapies Conc...
PD-1 blockade, which reinvigorates the tumor-reactive CD8+T cells by removing the inhibition induced by the interaction of PD-1 and PD-L1, has achieved high success in mediating complete, durable responses in patients with advanced or conventional therapy-resistant cancers; however, the successes ...
γδ T cells have the unique ability to detect a wide range of tumors with low mutation burdens, making them attractive candidates for CAR-T-cell therapy. Unlike αβ T cells and other immune cells, γδ T cells are superior in MHC non-restriction, selec
PD-1 antibody (nivolumab) to non-hNSG mice had no effect on the tumor size and growth, because tumors in both vehicle- and anti-PD-1-treated animals reached similar volume after days 10–12 of therapy (corresponding to two cycles of i.v. administered anti-PD-1 antibody). However, ...
forward the first anti-PD-1 therapy for advanced melanoma in China.” “The approval of our anti-PD-1 therapy reflects the Chinese government’s strong commitment to expedite the introduction of innovative therapies to Chinese patients,” said Joseph Romanelli, president of MSD ...
After 4 cycles of pembrolizumab CT scans showed new and increased size of the lung lesions, which stabilized during subsequent months without any further therapy. Our clinical cases provide evidence for the potential efficacy of an anti-PD-1 antibody in NMSCs. Although NMSCs are considered to ...
Although rare (<5%), clinical response to anti-PD-1 antibody may be preceded by "pseudoprogression" -- increase in the size and number of tumor lesions before actual tumor shrinkage. We report a case of pseudoprogression followed by an excellent response in an HCC patient treated with ...
摘要: 程序性细胞死亡-1 (PD-1) 免疫检查点抑制剂在多种肿瘤中显示出良好的疗效。在这里,我们报告一个不可切除的局部进展期胃癌 (GC) 与程序性细胞死亡 ligand-1 (PD-L1) 阳性和微卫星不稳定 (MSI),作为一线治疗方案,单剂量的 anti-PD-1 联合化疗治疗后,病理完全缓解 (pCR) 表现出意想不到的疗效。一...
Co-administration of anti-PD-1 Ab may reactivate phagocytic activity of BMDMs by disrupting nintedanib-induced immunosuppressive signal. Conclusions Combination therapy of anti-PD-1 Ab plus nintedanib exerts synergistic antitumor activity and can become a novel therapeutic option for patients with MPM. ...